Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 1, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Shire plc (NASDAQ: SHPG), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Johnson & Johnson (NYSE: JNJ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6895-100free.
Shire plc Research Reports
On September 24, 2014, Shire plc (Shire) announced that it has reached a final agreement with the U.S. government to pay $56.5 million to resolve a previously disclosed civil investigation of its sales and marketing practices for a period ending in 2010 relating to ADDERALL XR, VYVANSE DAYTRANA, LIALDA and PENTASA. In addition, Shire will pay $2.9 million to resolve a civil complaint filed by the State of Louisiana over marketing practices for certain drugs violating the state law. As part of the settlement, Shire said it has also entered into a five-year Corporate Integrity Agreement with the Office of Inspector General for the Department of Health and Human Services. "The Company has had, and will continue to have, a comprehensive compliance program and internal controls to ensure we comply with applicable laws and regulations," said Shire's CEO Flemming Ornskov. The full research reports on Shire are available to download free of charge at:
Merck & Co. Inc. Research Reports
On September 28, 2014, Merck & Co. Inc. (Merck) announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) - the Company's anti-PD-1 therapy - in PD-L1 positive, advanced gastric cancer at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain. According to the Company, its KEYTRUDA monotherapy achieved 31% overall response rate in patients with PD-L1 positive, advanced gastric cancer. "We are encouraged by the signals of anti-tumor activity in advanced gastric cancer, and are eager to move ahead with the Phase 2 study to better understand the potential of KEYTRUDA in advanced gastric cancer," said Dr. Alise Reicin, Vice President, Oncology, Merck Research Laboratories. Merck informed that the Phase II study will be initiated in Q1 2015. The full research reports on Merck are available to download free of charge at:
Medtronic, Inc. Research Reports
On September 25, 2014, Medtronic, Inc. (Medtronic) announced a five-year, $6 million funding commitment from Medtronic Philanthropy to support projects that seek to reduce premature mortality resulting from Rheumatic Fever (RF) and Rheumatic Heart Disease (RHD). The Company informed that the funding will support projects in three countries, yet to be ascertained. According to the World Heart Federation, RHD is the most commonly acquired heart disease in children in many of the world's poorest countries. "A strep throat infection should not be a death sentence because of where you live," said Dr. Jacob Gayle, Vice President, Medtronic Philanthropy. "We don't fear RHD in industrialized countries because it is the most preventable form of cardiovascular disease. How we treat it is as an indicator of the overall strength of a community's health system and its capacity to reach underserved populations," Gayle added. The full research reports on Medtronic are available to download free of charge at:
Salix Pharmaceuticals Ltd. Research Reports
On September 23, 2014, Bloomberg Businessweek reported that the merger talks between Salix Pharmaceuticals Ltd. (Salix) and Allergan Inc. (Allergan) are active again after around a couple of months when the two companies began discussions but failed to reach an agreement over the price of acquisition. As per the report, Allergan has been looking to acquire Salix in its effort to thwart a hostile takeover offer from Valeant Pharmaceuticals. The full research reports on Salix are available to download free of charge at:
Johnson & Johnson Research Reports
On September 24, 2014, Janssen Pharmaceuticals, Inc. (Janssen), a pharmaceutical company of Johnson & Johnson, announced the results of a first-of-its-kind study, The Impact of JANSSEN CONNECT Injection Centers on Adherence to an Atypical Long-Acting Injectable Antipsychotic among Patients with Schizophrenia Enrolled in a Support Program. The study showed that JANSSEN CONNECT patients who received their Janssen long-acting treatment (JLAT) at an injection center and remained in the program for more than six months were 4.5 times more likely to be adherent to their medication than those within the program who did not select this offering. "The JANSSEN CONNECT program was born out of our dedication to helping people living with schizophrenia navigate through the difficulties of living with the disease and staying on medication as prescribed by their healthcare provider," said Catherine Tak Piech, Vice President, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC. The full research reports on Johnson & Johnson are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review